Impact of high iron intake on cognition and neurodegeneration in humans and in animal models: a systematic review

Nutrition Reviews

Volumn 75, Issue 6, 2017, Pages 456-470

  Agrawal, Sonal ^a   Berggren, Kiersten L ^b   Marks, Eileen ^c   Fox, Jonathan H ^a  

^a UNIVERSITY OF WYOMING   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

brain aging; iron nutrition; iron supplementation; protein misfolding neurodegenerative diseases

Indexed keywords

NEUROTRANSMITTER; IRON;

ARTICLE; BRAIN FUNCTION; COCHRANE LIBRARY; COGNITION; COGNITIVE DEFECT; DEGENERATIVE DISEASE; HUMAN; IRON DEFICIENCY; IRON INTAKE; MEDLINE; MILD COGNITIVE IMPAIRMENT; MORPHOMETRY; NERVE DEGENERATION; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PARKINSONISM; PREFERRED REPORTING ITEMS FOR SYSTEMATIC REVIEWS AND META-ANALYSES; PUBLICATION BIAS; SCOPUS; SYSTEMATIC REVIEW; ADMINISTRATION AND DOSAGE; AGING; ANIMAL; ANIMAL BEHAVIOR; BLOOD; BRAIN; DEFICIENCY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; FACTUAL DATABASE; IRON DEFICIENCY ANEMIA; META ANALYSIS (TOPIC); METABOLISM; NUTRITIONAL STATUS; OBSERVATIONAL STUDY; PRECLINICAL STUDY; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT;

AGING; ANEMIA, IRON-DEFICIENCY; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; COGNITION; DATABASES, FACTUAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; IRON; IRON, DIETARY; META-ANALYSIS AS TOPIC; NUTRITIONAL STATUS; OBSERVATIONAL STUDIES AS TOPIC; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT;

EID: 85032362386     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1093/NUTRIT/NUX015     Document Type: Article

References (88)

1. Wu LL, Zhang L, Shao J, et al. Effect of perinatal iron deficiency on myelination and associated behaviors in rat pups. Behav Brain Res. 2008;188:263-270.
2. Brunette KE, Tran PV, Wobken JD, et al. Gestational and neonatal iron deficiency alters apical dendrite structure of CA1 pyramidal neurons in adult rat hippocampus. Dev Neurosci. 2010;32:238-248.
3. Daubner SC, Le T, Wang S. Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem Biophys. 2011;508:1-12.
4. Holmes-Hampton GP, Chakrabarti M, Cockrell AL, et al. Changing iron content of the mouse brain during development. Metallomics. 2012;4:761-770.
5. Chen JH, Shahnavas S, Singh N, et al. Stable iron isotope tracing reveals significant brain iron uptake in adult rats. Metallomics. 2013;5:167-173.
6. Baltussen R, Knai C, Sharan M. Iron fortification and iron supplementation are cost-effective interventions to reduce iron deficiency in four subregions of the world. J Nutr. 2004;134:2678-2684.
7. Murray-Kolb LE, Beard JL. Iron treatment normalizes cognitive functioning in young women. Am J Clin Nutr. 2007;85:778-787.
8. Scott SP, Murray-Kolb LE. Iron status is associated with performance on executive functioning tasks in nonanemic young women. J Nutr. 2016;146:30-37.
9. Lozoff B, Beard J, Connor J, et al. Long-lasting neural and behavioral effects of iron deficiency in infancy. Nutr Rev. 2006;64(5 pt 2):S34-S43; discussion S72-S91.
10. Bailey RL, Gahche JJ, Lentino CV, et al. Dietary supplement use in the United States, 2003-2006. J Nutr. 2011;141:261-266.
11. Hardiman O, Doherty CP, eds. Neurodegenerative Disorders: A Clinical Guide. London, UK: Springer; 2011.
12. Thal DR, Del Tredici K, Braak H. Neurodegeneration in normal brain aging and disease. Sci Aging Knowledge Environ. 2004;2004:pe26. doi:10.1126/sageke. 2004.23.pe26.
13. DiFiglia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997;277:1990-1993.
14. Guerrero EN, Wang H, Mitra J, et al. TDP-43/FUS in motor neuron disease: complexity and challenges. Prog Neurobiol. 2016;145-146:78-97.
15. Hallgren B, Sourander P. The effect of age on the non-haemin iron in the human brain. J Neurochem. 1958;3:41-51.
16. Ghadery C, Pirpamer L, Hofer E, et al. R2* mapping for brain iron: associations with cognition in normal aging. Neurobiol Aging. 2015;36:925-932.
17. Raven EP, Lu PH, Tishler TA, et al. Increased iron levels and decreased tissue integrity in hippocampus of Alzheimer's disease detected in vivo with magnetic resonance imaging. J Alzheimers Dis. 2013;37:127-136.
18. He N, Ling H, Ding B, et al. Region-specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping. Hum Brain Mapp. 2015;36:4407-4420.
19. Rosas HD, Chen YI, Doros G, et al. Alterations in brain transition metals in Huntington disease: an evolving and intricate story. Arch Neurol. 2012;69:887-893.
20. Ignjatovic A, Stevic Z, Lavrnic S, et al. Brain iron MRI: a biomarker for amyotrophic lateral sclerosis. J Magn Reson Imaging. 2013;38:1472-1479.
21. Elder GA, Gama Sosa MA, De Gasperi R. Transgenic mouse models of Alzheimer's disease. Mt Sinai J Med. 2010;77:69-81.
22. Duty S, Jenner P. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol. 2011;164:1357-1391.
23. Philips T, Rothstein JD. Rodent models of amyotrophic lateral sclerosis. Curr Protoc Pharmacol. 2015;69:5.67.1-5.67.21.
24. Ferrante RJ. Mouse models of Huntington's disease and methodological considerations for therapeutic trials. Biochim Biophys Acta. 2009;1792:506-520.
25. Li K, Reichmann H. Role of iron in neurodegenerative diseases. J Neural Transm (Vienna). 2016;123:389-399.
26. Nunez MT, Urrutia P, Mena N, et al. Iron toxicity in neurodegeneration. Biometals. 2012;25:761-776.
27. Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium and Zinc. Washington, DC: National Academy Press; 2001.
28. Fleming DJ, Jacques PF, Tucker KL, et al. Iron status of the free-living, elderly Framingham Heart Study cohort: an iron-replete population with a high prevalence of elevated iron stores. Am J Clin Nutr. 2001;73:638-646.
29. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. doi:10.1371/journal.pmed.1000097.
30. Institute for Laboratory Animal Research, National Research Council. Guidance for the Description of Animal Research in Animal Research in Scientific Publications. Washington, DC: National Academies Press; 2011.
31. Krauth D, Woodruff TJ, Bero L. Instruments for assessing risk of bias and other methodological criteria of published animal studies: a systematic review. Environ Health Perspect. 2013;121:985-992.
32. Zeng X, Zhang Y, Kwong JS, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015;8:2-10.
33. Lavich IC, de Freitas BS, Kist LW, et al. Sulforaphane rescues memory dysfunction and synaptic and mitochondrial alterations induced by brain iron accumulation. Neuroscience. 2015;301:542-552.
34. Budni P, de Lima MN, Polydoro M, et al. Antioxidant effects of selegiline in oxidative stress induced by iron neonatal treatment in rats. Neurochem Res. 2007;32:965-972.
35. de Lima MN, Laranja DC, Caldana F, et al. Selegiline protects against recognition memory impairment induced by neonatal iron treatment. Exp Neurol. 2005;196:177-183.
36. de Lima MN, Presti-Torres J, Caldana F, et al. Desferoxamine reverses neonatal iron-induced recognition memory impairment in rats. Eur J Pharmacol. 2007;570:111-114.
37. de Lima MN, Presti-Torres J, Garcia VA, et al. Amelioration of recognition memory impairment associated with iron loading or aging by the type 4-specific phosphodiesterase inhibitor rolipram in rats. Neuropharmacology. 2008;55:788-792.
38. Dornelles AS, Garcia VA, de Lima MN, et al. mRNA expression of proteins involved in iron homeostasis in brain regions is altered by age and by iron overloading in the neonatal period. Neurochem Res. 2010;35:564-571.
39. Fernandez LL, de Lima MN, Scalco F, et al. Early post-natal iron administration induces astroglial response in the brain of adult and aged rats. Neurotox Res. 2011;20:193-199.
40. Figueiredo LS, de Freitas BS, Garcia VA, et al. Iron loading selectively increases hippocampal levels of ubiquitinated proteins and impairs hippocampus-dependent memory. Mol Neurobiol. 2016;53:6228-6239.
41. Fredriksson A, Schroder N, Eriksson P, et al. Neonatal iron exposure induces neurobehavioural dysfunctions in adult mice. Toxicol Appl Pharmacol. 1999;159:25-30.
42. Fredriksson A, Schroder N, Eriksson P, et al. Maze learning and motor activity deficits in adult mice induced by iron exposure during a critical postnatal period. Brain Res Dev Brain Res. 2000;119:65-74.
43. Isaac G, Fredriksson A, Danielsson R, et al. Brain lipid composition in postnatal iron-induced motor behavior alterations following chronic neuroleptic administration in mice. FEBS J. 2006;273:2232-2243.
44. Perez VP, de Lima MN, da Silva RS, et al. Iron leads to memory impairment that is associated with a decrease in acetylcholinesterase pathways. Curr Neurovasc Res. 2010;7:15-22.
45. Rech RL, de Lima MN, Dornelles A, et al. Reversal of age-associated memory impairment by rosuvastatin in rats. Exp Gerontol. 2010;45:351-356.
46. Schroder N, Fredriksson A, Vianna MR, et al. Memory deficits in adult rats following postnatal iron administration. Behav Brain Res. 2001;124:77-85.
47. da Silva VK, de Freitas BS, da Silva Dornelles A, et al. Cannabidiol normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload: implications for neuroprotection. Mol Neurobiol. 2014;49:222-233.
48. Silva PF, Garcia VA, Dornelles AS, et al. Memory impairment induced by brain iron overload is accompanied by reduced H3K9 acetylation and ameliorated by sodium butyrate. Neuroscience. 2012;200:42-49.
49. de Lima MN, Polydoro M, Laranja DC, et al. Recognition memory impairment and brain oxidative stress induced by postnatal iron administration. Eur J Neurosci. 2005;21:2521-2528.
50. Fagherazzi EV, Garcia VA, Maurmann N, et al. Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders. Psychopharmacology (Berlin). 2012;219:1133-1140.
51. Miwa CP, de Lima MN, Scalco F, et al. Neonatal iron treatment increases apoptotic markers in hippocampal and cortical areas of adult rats. Neurotox Res. 2011;19:527-535.
52. Fredriksson A, Schroder N, Archer T. Neurobehavioural deficits following postnatal iron overload: I spontaneous motor activity. Neurotox Res. 2003;5:53-76.
53. Wang X, Wang M, Yang L, et al. Inhibition of Sirtuin 2 exerts neuroprotection in aging rats with increased neonatal iron intake. Neural Regen Res. 2014;9:1917-1922.
54. Archer T, Fredriksson A. Functional consequences of iron overload in catecholaminergic interactions: the Youdim factor. Neurochem Res. 2007;32:1625-1639.
55. Berggren KL, Chen J, Fox J, et al. Neonatal iron supplementation potentiates oxidative stress, energetic dysfunction and neurodegeneration in the R6/2 mouse model of Huntington's disease. Redox Biol. 2015;4:363-374.
56. Billings JL, Hare DJ, Nurjono M, et al. Effects of neonatal iron feeding and chronic clioquinol administration on the parkinsonian human a53t transgenic mouse. ACS Chem Neurosci. 2016;7:360-366.
57. Chen H, Wang X, Wang M, et al. Behavioral and neurochemical deficits in aging rats with increased neonatal iron intake: Silibinin's neuroprotection by maintaining redox balance. Front Aging Neurosci. 2015;7:206. doi:10.3389/fnagi.2015.00206.
58. Dal-Pizzol F, Klamt F, Frota ML Jr, et al. Neonatal iron exposure induces oxidative stress in adult Wistar rat. Brain Res Dev Brain Res. 2001;130:109-114.
59. Fernandez LL, Carmona M, Portero-Otin M, et al. Effects of increased iron intake during the neonatal period on the brain of adult AbPP/PS1 transgenic mice. J Alzheimers Dis. 2010;19:1069-1080.
60. Fredriksson A, Archer T. Effect of postnatal iron administration on MPTP-induced behavioral deficits and neurotoxicity: behavioral enhancement by L-Dopa-MK-801 co-administration. Behav Brain Res. 2003;139:31-46.
61. Fredriksson A, Archer T. Subchronic administration of haloperidol influences the functional deficits of postnatal iron administration in mice. Neurotox Res. 2006;9:305-312.
62. Fredriksson A, Schroder N, Eriksson P, et al. Neonatal iron potentiates adult MPTP-induced neurodegenerative and functional deficits. Parkinsonism Relat Disord. 2001;7:97-105.
63. Kaur D, Peng J, Chinta SJ, et al. Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. Neurobiol Aging. 2007;28:907-913.
64. Peng J, Oo ML, Andersen JK. Synergistic effects of environmental risk factors and gene mutations in Parkinson's disease accelerate age-related neurodegeneration. J Neurochem. 2010;115:1363-1373.
65. Peng J, Peng L, Stevenson FF, et al. Iron and paraquat as synergistic environmental risk factors in sporadic Parkinson's disease accelerate age-related neurodegeneration. J Neurosci. 2007;27:6914-6922.
66. Berggren KL, Lu Z, Fox JA, et al. Neonatal iron supplementation induces striatal atrophy in female YAC128 Huntington's disease nice. J Huntingtons Dis. 2016;5:53-63.
67. Hagemeier J, Tong O, Dwyer MG, et al. Effects of diet on brain iron levels among healthy individuals: an MRI pilot study. Neurobiol Aging. 2015;36:1678-1685.
68. Hernandez Mdel C, Allan J, Glatz A, et al. Exploratory analysis of dietary intake and brain iron accumulation detected using magnetic resonance imaging in older individuals: the Lothian Birth Cohort 1936. J Nutr, Health Aging. 2015;19:64-69.
69. Logroscino G, Gao X, Chen H, et al. Dietary iron intake and risk of Parkinson's disease. Am J Epidemiol. 2008;168:1381-1388.
70. Powers KM, Smith-Weller T, Franklin GM, et al. Dietary fats, cholesterol and iron as risk factors for Parkinson's disease. Parkinsonism Relat Disord. 2009;15:47-52.
71. Powers KM, Smith-Weller T, Franklin GM, et al. Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology. 2003;60:1761-1766.
72. Anderson C, Checkoway H, Franklin GM, et al. Dietary factors in Parkinson's disease: the role of food groups and specific foods. Mov Disord. 1999;14:21-27.
73. Blasco G, Puig J, Daunis IEJ, et al. Brain iron overload, insulin resistance, and cognitive performance in obese subjects: a preliminary MRI case-control study. Diabetes Care. 2014;37:3076-3083.
74. Andreeva VA, Galan P, Arnaud J, et al. Midlife iron status is inversely associated with subsequent cognitive performance, particularly in perimenopausal women. J Nutr. 2013;143:1974-1981.
75. Umur EE, Oktenli C, Celik S, et al. Increased iron and oxidative stress are separately related to cognitive decline in elderly. Geriatr Gerontol Int. 2011;11:504-509.
76. Mueller C, Schrag M, Crofton A, et al. Altered serum iron and copper homeostasis predicts cognitive decline in mild cognitive impairment. J Alzheimers Dis. 2012;29:341-350.
77. Milward EA, Bruce DG, Knuiman MW, et al. A cross-sectional community study of serum iron measures and cognitive status in older adults. J Alzheimers Dis. 2010;20:617-623.
78. Schiepers OJ, van Boxtel MP, de Groot RH, et al. Serum iron parameters, HFE C282Y genotype, and cognitive performance in older adults: results from the FACIT study. J Gerontol A Biol Sci Med Sci. 2010;65:1312-1321.
79. Gao S, Jin Y, Unverzagt FW, et al. Trace element levels and cognitive function in rural elderly Chinese. J Gerontol A Biol Sci Med Sci. 2008;63:635-641.
80. Lam PK, Kritz-Silverstein D, Barrett Connor E, et al. Plasma trace elements and cognitive function in older men and women: the Rancho Bernardo study. J Nutr Health Aging. 2008;12:22-27.
81. Modgil S, Lahiri DK, Sharma VL, et al. Role of early life exposure and environment on neurodegeneration: implications on brain disorders. Transl Neurodegener. 2014;3:9. doi:10.1186/2047-9158-3-9.
82. Devasthali SD, Gordeuk VR, Brittenham GM, et al. Bioavailability of carbonyl iron: a randomized, double-blind study. Eur J Haematol. 1991;46:272-278.
83. Dewey KG, Finley DA, Lonnerdal B. Breast milk volume and composition during late lactation (7-20 months). J Pediatr Gastroenterol Nutr. 1984;3:713-720.
84. Dewey KG, Lonnerdal B. Milk and nutrient intake of breast-fed infants from 1 to 6 months: relation to growth and fatness. J Pediatr Gastroenterol Nutr. 1983;2:497-506.
85. Lonnerdal B. Effects of milk and milk components on calcium, magnesium, and trace element absorption during infancy. Physiol Rev. 1997;77:643-669.
86. Ayton S, Lei P. Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration. Biomed Res Int. 2014;2014:581256. doi:10.1155/2014/581256.
87. Wang W, Knovich MA, Coffman LG, et al. Serum ferritin: past, present and future. Biochim Biophys Acta. 2010;1800:760-769.
88. Nemeth E, Ganz T. Anemia of inflammation. Hematol Oncol Clin North Am. 2014;28:671-681.